Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.

Oncogene - 10 May 2012

Ward P S, Cross J R, Lu C, Weigert O, Abel-Wahab O, Levine R L, Weinstock D M, Sharp K A, Thompson C B

Abstract excerpt

Mutations in cytosolic isocitrate dehydrogenase 1 (IDH1) or its mitochondrial homolog IDH2 can lead to R(-)-2-hydroxyglutarate (2HG) production. To date, mutations in three active site arginine residues, IDH1 R132, IDH2 R172 and IDH2 R140, have been shown to result in the neomorphic production of 2HG. Here we report on three additional 2HG-producing IDH1 mutations: IDH1 R100, which is affected in adult glioma,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Cytosol
Share to Glutarates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Share to Mitochondria

Share to Mutation

Share to Neoplasms

Share to Polymorphism, Single Nucleotide

Source

Open in PubMed Open full text

Identifiers

PMID: 21996744
DOI: 10.1038/onc.2011.416
PMCID: PMC3271133

Genes

IDH1
IDH2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.PMID 21996744Read ↗

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.Semantic proximity Read ↗

Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability.Semantic proximity Read ↗

Isocitrate dehydrogenase gene variants in cancer and their clinical significance.Semantic proximity Read ↗

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectivesSemantic proximity Read ↗

Catalytically distinct metabolic enzyme isocitrate dehydrogenase 1 mutants tune phenotype severity in tumor models.Semantic proximity Read ↗

Metabolic consequences of oncogenic IDH mutations.Semantic proximity Read ↗

The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.Semantic proximity Read ↗

The implications of IDH mutations for cancer development and therapy.Semantic proximity Read ↗

Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma.Semantic proximity Read ↗

Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations.Semantic proximity Read ↗

Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities.Semantic proximity Read ↗

What do we know about IDH1/2 mutations so far, and how do we use it?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.